KR950703342A - 수용액 - Google Patents

수용액 Download PDF

Info

Publication number
KR950703342A
KR950703342A KR1019950701033A KR19950701033A KR950703342A KR 950703342 A KR950703342 A KR 950703342A KR 1019950701033 A KR1019950701033 A KR 1019950701033A KR 19950701033 A KR19950701033 A KR 19950701033A KR 950703342 A KR950703342 A KR 950703342A
Authority
KR
South Korea
Prior art keywords
aqueous solution
hydroxypropoxy
dimethoxybenzyl
amino
weight
Prior art date
Application number
KR1019950701033A
Other languages
English (en)
Other versions
KR0178308B1 (ko
Inventor
유조 기무아
신이찌 이시가와
요시도 마쓰다
Original Assignee
오스카 아끼아꼬
오스카 세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오스카 아끼아꼬, 오스카 세이야꾸 가부시끼가이샤 filed Critical 오스카 아끼아꼬
Publication of KR950703342A publication Critical patent/KR950703342A/ko
Application granted granted Critical
Publication of KR0178308B1 publication Critical patent/KR0178308B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1. 청구범위에 기재된 발명이 속한 기술분야; 본 발명은 물에 대해 용해하기 어려운 약염기성화합물을 포함하고 약제에 유용한 수용액에 관한 것이다.
2. 발명이 해결하려고 하는 기술적 과제; 본 발명의 목적은 유효성분의 활성성분으로서 6-[3-(3,4-디메톡시벤질)아미노-2-히드록시프로폭시]카르보스티릴 또는 그 염과 용해보조제로서 DL-락트산 및 임의의 종래의 첨가제로 구성된 수용액을 제공하기 위한 것이다.
3. 발명의 해결방법의 요지; 6-[3-(3,4-디메톡시벤질)아미노-2-히드록시프로폭시]카르보스티릴 또는 염을 유효성분으로서 함유하고 다시 또 용해보조제로서 DL-락트산과 종래의 첨가제를 함유하는 것을 특징으로 하는 수용액.
4. 발명의 중요한 용도; 본 발명의 목적은 유효성분의 활성성분으로서 6-[3-(3,4-디메톡시벤질)아미노-2-히드록시프로폭시]카르보스티릴 또는 염과 용해보조제로서 DL-락트산 및 임의의 종래의 첨가제로 구성된 수용액을 제공하기 위한 것이다.]

Description

수용액
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 6-[3-(3,4-디메톡시벤질)아미노-2-히드록시프로폭시]카르보스티릴 또는 염을 유효성분으로서 함유하고 다시 도 용해보조제로서 DL-락트산과 종래이 첨가제를 함유하는 것을 특징으로 하는 수용액.
  2. 제1항에 있어서, 활성화합물인 6-[3-(3,4-디메톡시벤질)아미노-2-히드록시프로폭시]카르보스티릴 또는 염이 전체조성물에 대해 0.01 내지 70중량% 함유되어 있는 것을 특징으로 하는 수용액.
  3. 제1항에 있어서, DL-락트산이 활성화합물인 6-[3-(3,4-디메톡시벤질)아미노-2-히드록시프로폭시]카르보스티릴 또는 염 100중량부에 대해 1 내지 2000중량부 사용되는 것을 특징으로 하는 수용액.
  4. 제3항에 있어서, DL-락트산이 활성화합물인 6-[3-(3,4-디메톡시벤질)아미노-2-히드록시프로폭시]카르보스티릴 또는 염 100중량부에 대해 10 내지 2000중량부의 범위에서 사용되는 것을 특징으로 하는 수용액.
  5. 제3항에 있어서, DL-락트산이 활성화합물인 6-[3-(3,4-디메톡시벤질)아미노-2-히드록시프로폭시]카르보스티릴 또는 염 100중량부에 대해 20 내지 80중량부의 범위에서 사용되는 것을 특징으로 하는 수용액.
  6. 제3항에 있어서, DL-락트산이 활성화합물인 6-[3-(3,4-디메톡시벤질)아미노-2-히드록시프로폭시]카르보스티릴 또는 염 100중량부에 대해 30 내지 60중량부의 범위에서 사용되는 것을 특징으로 하는 수용액.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950701033A 1993-07-28 1994-07-25 수용액 KR0178308B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP18597393 1993-07-28
JP93-185973 1993-07-28
PCT/JP1994/001222 WO1995003802A1 (en) 1993-07-28 1994-07-25 Aqueous composition

Publications (2)

Publication Number Publication Date
KR950703342A true KR950703342A (ko) 1995-09-20
KR0178308B1 KR0178308B1 (ko) 1999-03-20

Family

ID=16180120

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950701033A KR0178308B1 (ko) 1993-07-28 1994-07-25 수용액

Country Status (15)

Country Link
US (1) US5686440A (ko)
EP (1) EP0662833B1 (ko)
KR (1) KR0178308B1 (ko)
CN (1) CN1060041C (ko)
AT (1) ATE207358T1 (ko)
AU (1) AU669451B2 (ko)
CA (1) CA2144729A1 (ko)
DE (1) DE69428771T2 (ko)
DK (1) DK0662833T3 (ko)
ES (1) ES2166375T3 (ko)
GR (1) GR3037007T3 (ko)
PH (1) PH31591A (ko)
PT (1) PT662833E (ko)
TW (1) TW254855B (ko)
WO (1) WO1995003802A1 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164570A (en) * 1973-09-24 1979-08-14 David Clough Stabilized aqueous catecholamine solutions
DE3333719A1 (de) * 1983-09-17 1985-04-04 Bayer Ag Loesungen milchsaurer salze von piperazinylchinolon- und piperazinyl-azachinoloncarbonsaeuren
EP0355583B1 (en) * 1988-08-10 1995-01-25 Otsuka Pharmaceutical Co., Ltd. Cardiotonics

Also Published As

Publication number Publication date
EP0662833B1 (en) 2001-10-24
US5686440A (en) 1997-11-11
ES2166375T3 (es) 2002-04-16
TW254855B (ko) 1995-08-21
ATE207358T1 (de) 2001-11-15
CA2144729A1 (en) 1995-02-09
KR0178308B1 (ko) 1999-03-20
PT662833E (pt) 2002-02-28
CN1113074A (zh) 1995-12-06
AU669451B2 (en) 1996-06-06
GR3037007T3 (en) 2002-01-31
WO1995003802A1 (en) 1995-02-09
PH31591A (en) 1998-11-03
DE69428771D1 (de) 2001-11-29
DE69428771T2 (de) 2002-05-08
CN1060041C (zh) 2001-01-03
EP0662833A1 (en) 1995-07-19
AU7237894A (en) 1995-02-28
DK0662833T3 (da) 2001-12-03

Similar Documents

Publication Publication Date Title
BR9612661A (pt) Utilização de uma combinaç i de tensoatives agentes quelantes e óleos essenciais para desinfecção eficaz
DK1301077T3 (da) Antimikrobielt præparat, som er nyttigt til behandling af bovin mastitis
PE20010400A1 (es) Formulacion de sal comun y moxifloxacina
ES2145900T3 (es) Composiciones lubricantes.
ES2194991T3 (es) Composiciones no acuosas conteniendo un compuesto haloalquinilo y un tampon para promover actividad biocida y para estabilizar las composiciones finales.
DE69424775D1 (de) Verbessertes, wässriges funktionelles fluidum
KR950703342A (ko) 수용액
DE69315836D1 (de) Pyrazolpyridine für die behandlung der anämie
KR930019808A (ko) 세정제 조성물
TR199501574A2 (tr) Iyi bir tampon etkisine sahip azotsuz paslanmaya karsi koruyucu maddeler.
MX9301627A (es) Agente para utilizarse como un antiirritante y composicion que lo contiene.
DK1349457T3 (da) Væskeformige antimikrobemidler
DK0857017T3 (da) Præparat til behandling af strøelse til fjerkræ
DK0639049T3 (da) Halogenerede 4'-methoxyacetophenoner som mikrobicider og konserveringsmidler
KR890009270A (ko) 식물 보호용 살균제
KR880013453A (ko) 제초제 조성물
KR900013959A (ko) γ-카르블린 또는 그들의 제약학적으로 허용 가능한 산부가염 및/또는 수화물, 및 그들로 구성되는 제약학적 조성물
JPS55108805A (en) Repellent for insect and termite
ATE327235T1 (de) 1,2,5,10-tetrahydropyridazino 4,5-böchinolin-1, 0-dione und ihre anwendung in der behandlung von schmerzen

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20031106

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee